New Cancer Drug Approvals: Less Than Half Of Important Clinical Trial Uncertainties Reported By The FDA To Clinicians, 2019–22
Health Affairs · 2025
DOI: 10.1377/hlthaff.2024.01134 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Affairs, 2025. Verfasst von Avi Cherla und 6 weiteren Autor:innen. Beteiligte Einrichtung: Avi Cherla (a.j.cherla@lse.ac.uk), London School of Economics and Political Science, London, United Kingdom. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Drug Approval, Antineoplastic Agents, Clinical Trials as Topic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
Uncertainties about the benefits and harms of new drugs are common at the time of drugs' approval. It is unclear to what extent the Food and Drug Administration (FDA) communicates these uncertainties in the FDA-approved prescribing information (the drug label), which is the primary channel of communication between the FDA and physicians. Although physicians might not regularly consult the drug label for prescribing decisions, other information sources used by physicians either index or incorporate information from the label. We searched FDA review documents for uncertainties identified by FDA reviewers with new cancer drugs. We considered the subset of uncertainties highlighted in the FDA's Benefit-Risk Framework as important to the FDA's approval decision. During the period 2019-22, the FDA approved fifty-two new cancer drugs. In review documents, FDA reviewers identified a total of 213 clinical trial uncertainties with new cancer drugs, 50 percent of which were considered to be important uncertainties to the FDA's approval decision. Labels for physicians reported information on 26 percent of all uncertainties and 48 percent of uncertainties that were important to the FDA's approval decision. Communicating uncertainties about the evidence of drugs in the label is essential for informing physicians about drugs' safe and effective use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Avi Cherla (a.j.cherla@lse.ac.uk), London School of Economics and Political Science, London, United Kingdom.
- Steven Woloshin, Dartmouth College, Lebanon, New Hampshire.
- Anita K. Wagner, Harvard University and Harvard Pilgrim Health Care Institute, Boston, Massachusetts.
- Olivier J. Wouters, London School of Economics and Political Science.
- Courtney Davis, King's College London, London, United Kingdom.
- Elias Mossialos, London School of Economics and Political Science.
Zitieren
APA
Cherla, A., Woloshin, S., Wagner, A. K., Wouters, O. J., Davis, C., Mossialos, E., & Naci, H. (2025). New Cancer Drug Approvals: Less Than Half Of Important Clinical Trial Uncertainties Reported By The FDA To Clinicians, 2019–22. Health Affairs. https://doi.org/10.1377/hlthaff.2024.01134
Vancouver
Cherla A, Woloshin S, Wagner AK, Wouters OJ, Davis C, Mossialos E, et al. New Cancer Drug Approvals: Less Than Half Of Important Clinical Trial Uncertainties Reported By The FDA To Clinicians, 2019–22. Health Affairs. 2025. doi:10.1377/hlthaff.2024.01134
BibTeX
@article{Cherla2025,
author = {Cherla, Avi and Woloshin, Steven and Wagner, Anita K and Wouters, Olivier J and Davis, Courtney and Mossialos, Elias and Naci, Huseyin},
title = {New Cancer Drug Approvals: Less Than Half Of Important Clinical Trial Uncertainties Reported By The FDA To Clinicians, 2019–22},
journal = {Health Affairs},
year = {2025},
doi = {10.1377/hlthaff.2024.01134}
}
EUVIMED